EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Tetanus Immunity in People Living with HIV: Reassessment of the Booster Dose Schedule

Şeyma Yavuz iD, Altan Aksoy, Sengül Üçer, Sami Kınıklı

AIDS Research and Human Retroviruses · 13.11.2026

DOI: 10.1177/08892229261507443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, online erschienen am 13.11.2026. Verfasst von Şeyma Yavuz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Microbiology, Ankara Training and Research Hospital, Ankara, Türkiye. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The decrease in CD4 + T lymphocyte count in people living with HIV causes a weakening of the immune response developed against the vaccine. This study aims to determine tetanus antibody levels in people living with HIV and to evaluate the relationship between these levels and various parameters. It aims to characterize those who lack protective antibody levels despite documented vaccination within the recommended 10-year interval and to question the adequacy of the current booster dose timing. Tetanus antibody levels were measured in serum samples from people living with HIV followed at the Infectious Diseases Clinic, using the Clostridium tetani toxin IgG (VIRCLIA; Vircell, Spain) kit by chemiluminescence immunoassay and interpreted according to the World Health Organization recommendations. All participants had a documented tetanus toxoid dose within the preceding 10 years, verified through the national Vaccination Tracking System. The study included 100 people living with HIV (88 men, 12 women; ages 20–73 years, mean = 38.04). Only age ( p < .001) and time since last vaccination ( p = .004) had a statistically significant effect on tetanus antibody levels. For protective levels (≥0.20 IU/mL), only age was significant ( p = .008), with higher protective levels in the 20–39 age group than in those over 40. Despite vaccination within the preceding 10 years, 17% ( n = 17) lacked protective antibody levels: 7.9% of those aged 20–39 versus 32.4% of those aged ≥40 (odds ratio = 5.57, 95% confidence interval: 1.77–17.48), and 25.0% of those vaccinated 5–10 years earlier versus 11.7% of those vaccinated within the previous 5 years. HIV-related clinical and immunological parameters were not significantly associated with tetanus antibody levels. Nevertheless, nearly one in five people living with HIV considered up-to-date lacked protective antibody levels, predominantly those aged ≥40 years. In this group, serological testing or a booster dose earlier than the recommended 10-year interval may be warranted.

Schlagwörter

Stichwörter der Autor:innen

HIVbooster doseprotective antibody leveltetanus

Autor:innen und Institutionen

  • Medical Microbiology, Ankara Training and Research Hospital, Ankara, Türkiye.
  • Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Türkiye.

ORCID-Profile: Şeyma Yavuz

Zitieren

APA

Yavuz, Ş., Aksoy, A., Üçer, S., & Kınıklı, S. (2026). Evaluation of Tetanus Immunity in People Living with HIV: Reassessment of the Booster Dose Schedule. AIDS Research and Human Retroviruses. https://doi.org/10.1177/08892229261507443

Vancouver

Yavuz Ş, Aksoy A, Üçer S, Kınıklı S. Evaluation of Tetanus Immunity in People Living with HIV: Reassessment of the Booster Dose Schedule. AIDS Research and Human Retroviruses. 2026. doi:10.1177/08892229261507443

BibTeX
@article{Yavuz2026,
  author = {Yavuz, Şeyma and Aksoy, Altan and Üçer, Sengül and Kınıklı, Sami},
  title = {Evaluation of Tetanus Immunity in People Living with HIV: Reassessment of the Booster Dose Schedule},
  journal = {AIDS Research and Human Retroviruses},
  year = {2026},
  doi = {10.1177/08892229261507443}
}
Kostenlos starten →